Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Syngene International Ltd

| Quarterly Financial Results Q3 FY 2025-26

NEUTRAL SENTIMENT

Report Source

⬤22nd Jan 26

Summary : Syngene reported Q3 and 9M 2025 unaudited results, showing revenue growth but profit decline due to exceptional items and write-offs, alongside strategic capacity expansion in India and USA.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Standalone Total expenses: Q3 2025: Rs. 7,530 million; YTD 2025: Rs. 22,448 million.
  2. Consolidated Total expenses: Q3 2025: Rs. 8,335 million; YTD 2025: Rs. 24,652 million.
  3. Significant expenses include cost of chemicals, employee benefits, and depreciation.
  4. Rs. 277 million net (Rs. 202 million after tax) written off as unrecoverable balances in receivables.
  5. Standalone Revenue from operations: Q3 2025: Rs. 8,344 million; YTD 2025: Rs. 24,638 million.
  6. Consolidated Revenue from operations: Q3 2025: Rs. 9,171 million; YTD 2025: Rs. 27,022 million.
  7. Reduction of contingent liability by Rs. 197 million due to Vivad se Vishwas Scheme settlement.
  8. Reserves (Other Equity) as of 31 March 2025: Rs. 42,364 million (standalone) / Rs. 43,243 million (consolidated).
  9. Capital Work in Progress (CWIP) related to USA acquisition: Rs. 2,981 million.
  10. Land capitalized for USA acquisition: Rs. 311 million.
  11. Consolidated revenue is higher than standalone, reflecting subsidiary contributions.
  12. Consolidated profit for the period (Q3 2025: Rs. 150 million) is lower than standalone (Q3 2025: Rs. 165 million), partly due to exceptional items.

Corporate Overview

  1. India (Bangalore)
  2. USA (Baltimore)
  3. Incremental impact of new Labour Codes on financial results (gratuity of Rs. 658-706 million).
  4. Write-off of Rs. 277 million in unrecoverable receivables due to foreign exchange rates.
  5. Providing Contract Research and Manufacturing Services (CRMS).
  6. Factual and compliant, reporting financial results and board decisions.
  7. Global customers for large molecule discovery, development, and manufacturing services.
  8. Contract Research and Manufacturing Services
  9. Increased total single-use bioreactor capacity to 50,000L.
  10. Acquisition of biologics site in USA to increase bioreactor capacity.
  11. Granted license for drug substance production line and bonded warehouse at Bangalore facility.

Risk Factors

  1. New Labour Codes impact financial results.
  2. Unrecoverable receivables from foreign exchange.
  3. Regulatory changes affect operational compliance.
  4. Potential for future foreign exchange losses.

Key Drivers

  1. Acquired US biologics manufacturing site.
  2. Expanded bioreactor capacity to 50,000L.
  3. Secured new drug substance production license.
  4. Enhanced global manufacturing network capabilities.

Auditor’s Report

  1. Unqualified limited review opinion for both standalone and consolidated financial results.

Board Commentary

  1. Recommended a final dividend of Rs. 1.25 per equity share of Rs. 10/-.
  2. Financial impact from new Labour Codes due to wage definition changes.
  3. Unrecoverable receivables due to cumulative foreign exchange rate changes.
  4. Settlement of pending TDS assessments under 'Vivad se Vishwas Scheme, 2024'.
  5. Assessment of financial impact from new Labour Codes (Code on Wages, Industrial Relations, Social Security, Occupational Safety, Health and Working Conditions).
  6. Acquisition of biologics site in USA (cost incurred till 31 March 2025: Rs. 2,981 million Capital Work in Progress, Rs. 311 million capitalized as Land).
  7. Capitalization of Rs. 3,438 million for property, plant and equipment from Bangalore biologics manufacturing facility.

Corporate Governance

  1. Audit Committee reviewed results on January 21, 2026.
  2. Board of Directors approved results on January 22, 2026.

Management Discussion & Analysis

Future Strategy

  1. Expanding global manufacturing network through acquisitions and capacity enhancements.

Operational Focus Areas

  1. Compliance with new Labour Codes and assessing financial impact.
  2. Integrating acquired biologics manufacturing capabilities.

Performance Drivers

  1. Revenue from operations (standalone: 24,638 million YTD; consolidated: 27,022 million YTD).

Risk Control Measures

  1. Monitoring finalization of Central/State Rules for Labour Codes and taking necessary compliance steps.

Critical Risks

  1. Financial impact from new Labour Codes due to wage definition changes.
  2. Unrecoverable receivables due to cumulative foreign exchange rate changes.